- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02027233
Clinical Trial to Assess the Influenza Vaccination of the Hospitalized Adults (FLUVAC EV-03)
Efficiency in Population of Influenza Vaccination for Flu Prevention of the Hospitalized Adults
This study assesses the seasonal of influenza vaccine effectiveness in adults hospitalised with laboratory-confirmed influenza through a network of hospitals in France.
Also, To better understand the burden of other respiratory viruses such as respiratory syncytial virus (RSV) and SARS-CoV-2 in hospitalized adults, we need to describe and quantify the population hospitalized due to theses other respiratory viruses.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Influenza vaccination strategies aim at protecting high-risk population from severe outcomes. Estimating the effectiveness of seasonal vaccines against influenza related hospitalisation is important to guide these strategies. The main objective is to measure the population effectiveness of influenza vaccine in patients hospitalized with virologically confirmed influenza laboratory result during all influenza seasons from 2013/2014 to 2021/2022 in a French hospital network. An interim analysis is provided for each influenza season and a global analysis of all seasons.
Each year, we also collect data from other respiratory viruses such as respiratory syncytial virus (RSV) on the hospitalized population. The data for three years confirm that, although RSV is less common than influenza in patients with flu-like symptom (4% of 1452 patients), it is responsible for serious complications at a higher frequency than influenza, especially in the elderly and immunosuppressed patients. To better understand the burden of disease of RSV infection in hospitalized adults, we need to start patients recruitment sooner at the start of the VRS epidemic.
With the recent emergence of the COVID-19 pandemic and our participation in European projects within the framework of COVID-19 surveillance, the FLUVAC study is an opportunity to collect additional data in patients hospitalized with a severe acute respiratory illness (SARI) which may be due to respiratory infection with an influenza virus or other respiratory viruses including SARS-CoV-2. We therefore propose to collect clinical (chronic diseases, comorbidities, intensive care), epidemiological and virological data throughout the year in adult patients hospitalized for suspected CO-VID-19.
This is a study "case-control" involving a nasopharyngeal sample for all hospitalised patients presenting a SARI within seven days. Cases will be patients RT-PCR positive for influenza. Controls will be patients negative for any influenza virus.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Fabrice Carrat, PU-PH
- Phone Number: +33(0)1 44 73 84 58
- Email: carrat@u707.jussieu.fr
Study Contact Backup
- Name: Odile Launay, PU-PH
- Phone Number: : +33(0)1 58 41 18 60
- Email: odile.launay@aphp.fr
Study Locations
-
-
-
Paris, France, 75654
- Institut National de la Santé et de la Recherche Médicale
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 year
- Affiliated with social security health insurance
- Written informed consent
- Patients hospitalized for at least 24 hours for one of the reasons indicated in Table 1 of protocol
- Presence of Influenza-like syndrome before the hospitalization (even if symptoms are not present at the time of inclusion), or less than 48 hours after the hospitalization
- Rapid completion of nasopharyngeal sample after hospitalization without exceeding 7 days after the onset of Influenza-like syndrome
Exclusion Criteria:
- Realization of nasopharyngeal sampling more than 7 days after the onset of symptoms
- Contraindication for influenza vaccine (Hypersensitivity to the active substances, to any of the excipients and to trace eg eggs, including ovalbumin, chicken protein)
- Patients institutionalized without regular community interaction
- Previously tested positive for any influenza virus in the current season (RT-PCR, multiplex RT-PCR)
- Patient under curatorship or under guardianship whose sample was obtained as part of their medical care but not complying with the conditions of Article L1121-8 of the Code de la Santé Publique.
- Patient under curatorship or under guardianship whose sample was not obtained as part of their medical care.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nasopharyngeal sample
Rapid completion of nasopharyngeal within 24 hours after hospitalization without exceeding 7 days after the onset
|
The nasopharyngeal sample will be used to find the types and subtypes of influenza virus and other respiratory viruses (VRS, SARS-CoV-2 and others).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure of vaccine efficacy in population by comparing the number of influenza cases virologically documented in hospitalized patients vaccinated and unvaccinated.
Time Frame: 9 years
|
The effectiveness of the vaccine in population will be calculated according to the formula VE = 1 - OR. an interval exact confidence of 95% will be calculated on the point estimate.
|
9 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure of vaccine efficacy in population by age group
Time Frame: 9 years
|
Measure of vaccine efficacy by comparing the number of influenza cases virologically documented in hospitalized patients vaccinated and unvaccinated according to age groups
|
9 years
|
Measure of vaccine efficacy in population by influenza type/subtype
Time Frame: 9 years
|
The objective is to compare the number of influenza cases virologically documented in hospitalized patients vaccinated and unvaccinated depending on the subtypes.
|
9 years
|
Description of the population hospitalized for syndrome acute respiratory infection (SARI)
Time Frame: 9 years
|
The objective is to :
|
9 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Odile Launay, PU-PH, Assistance Publique - Hôpitaux de Paris
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- C13-47
- 2013-A01204-41 (Registry Identifier: IDRCB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Acute Respiratory Infection
-
NeuroActiva, Inc.UnknownSevere Acute Respiratory Syndrome | Covid19 | Corona Virus Infection | Severe Acute Respiratory Syndrome (SARS) Pneumonia | Neurodegeneration | Neuroinflammatory Response | Severe Acute Respiratory Infection | Severe Acute Respiratory Syndrome of Upper Respiratory TractUnited States
-
NeuroActiva, Inc.Biomed Industries, Inc.RecruitingCoronavirus Infection | Severe Acute Respiratory Syndrome Coronavirus 2 | Severe Acute Respiratory InfectionUnited States
-
Australian and New Zealand Intensive Care Research...International Severe Acute Respiratory and Emerging Infection Consortium; The...RecruitingSevere Acute Respiratory InfectionAustralia
-
Mexican Emerging Infectious Diseases Clinical Research...National Institute of Allergy and Infectious Diseases (NIAID); Secretaria de...TerminatedSevere Acute Respiratory Infection (SARI)Mexico
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceCompletedCoronaviridae Infections | Nidovirales Infections | RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Coronavirus Infection | SARS (Severe Acute Respiratory Syndrome) | Respiratory Tract DiseaseFrench Guiana
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São Paulo; Hospital das Clínicas...UnknownCovid19 | Corona Virus Infection | SARS-CoV Infection | SARS (Severe Acute Respiratory Syndrome)Brazil
-
Hospices Civils de LyonCompletedSevere Acute Respiratory Syndrome Coronavirus 2 | Infection, CoronavirusFrance
-
Assistance Publique - Hôpitaux de ParisCompletedCoronaviridae Infections | Nidovirales Infections | RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases | Corona Virus Infection | SARS (Severe Acute Respiratory Syndrome)France
-
University of WashingtonNational Institute of Allergy and Infectious Diseases (NIAID); Fred Hutchinson...CompletedCOVID-19 | Coronavirus Infection | SARS-CoV-2 Infection | SARS (Severe Acute Respiratory Syndrome)United States
-
Hospital Universitari Joan XXIII de Tarragona.Sociedad Española de Medicina Intensiva,critica y unidades coronariasRecruiting
Clinical Trials on nasopharyngeal sample
-
University Hospital, RouenRecruitingAsthma | Asthma in ChildrenFrance
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Institut National de la Santé Et de la Recherche...SanofiUnknownAdult HospitalizedFrance
-
GlaxoSmithKlineCompletedRespiratory DisordersUnited Kingdom
-
Institut PasteurBiogroup Laboratoire de biologie médicaleNot yet recruiting
-
University of OxfordInnovative Medicines Initiative; Respiratory syncytial virus consortium in...Active, not recruitingRespiratory Syncytial Virus (RSV)United Kingdom
-
Radboud University Medical CenterUnknown
-
Assistance Publique - Hôpitaux de ParisPRODISS; WEEZEVENTCompleted
-
Assistance Publique - Hôpitaux de ParisRecruitingSARS-CoV2 InfectionFrance
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, France; Institut... and other collaboratorsCompletedCOVID-19 InfectionFrance